Literature DB >> 23589955

Botulinum toxin A and headache treatment.

Jacob Gady1, Elie M Ferneini.   

Abstract

PURPOSE: To determine whether botulinum toxin type A (BOTOX ) is effective for the prophylactic treatment of headaches in adults.
MATERIALS AND METHODS: A retrospective literature reviewwas performed. The outcome of various studies is discussed, including whether a decrease in the intensity as well as the occurrence of tension and migraine headaches was accomplished.
RESULTS: The approval for botulinum toxin A for the treatment of migraine was based largely on the results of Allergan's PREEMPT Phase III trial. The study demonstrated a statistically significant decrease in the frequency of headache days and a reduction in total headache hours in the treated group vs placebo. There have been several other randomized trials looking at treatment of chronic tension type headaches with botulinum toxin A therapy. Most studies show no difference in headache intensity between groups at anytime. Current concepts of the pathophysiology of tension-type headaches would suggest Botox to be a reasonable and likely effective treatment. However, its effectiveness in treatment of chronic migraine and tension-type headaches remains debatable.
CONCLUSION: The literature currently suggests a modest effect, if any, with the use of botulinum toxin A for the prophylactic treatment of chronic migraine and tension-type headache, and further prospective, randomized, double-blinded studies are needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23589955

Source DB:  PubMed          Journal:  Conn Med        ISSN: 0010-6178


  6 in total

1.  Treatment of Frontal Secondary Headache Attributed to Supratrochlear and Supraorbital Nerve Entrapment With Oral Medication or Botulinum Toxin Type A vs Endoscopic Decompression Surgery.

Authors:  Boris Filipovic; J Alexander de Ru; Sara Hakim; Rick van de Langenberg; Pepijn A Borggreven; Peter J F M Lohuis
Journal:  JAMA Facial Plast Surg       Date:  2018-09-01       Impact factor: 4.611

Review 2.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

3.  The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache.

Authors:  Malgorzata Pihut; Ewa Ferendiuk; Michal Szewczyk; Katarzyna Kasprzyk; Mieszko Wieckiewicz
Journal:  J Headache Pain       Date:  2016-03-24       Impact factor: 7.277

4.  Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain.

Authors:  Jiafu Wang; Jianghui Meng; Marc Nugent; Minhong Tang; J Oliver Dolly
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

5.  The Hanger Reflex: An Inexpensive and Non-invasive Therapeutic Modality for Dystonia and Neurological Disorders.

Authors:  Takashi Asahi; Takuto Nakamura; Michi Sato; Yuki Kon; Hiroyuki Kajimoto; Shuji Sato
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-10-16       Impact factor: 1.742

Review 6.  Orofacial pain management: current perspectives.

Authors:  Marcela Romero-Reyes; James M Uyanik
Journal:  J Pain Res       Date:  2014-02-21       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.